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Many cell populations, derived from both adult tissues and embryonic stem cells, show promise for the treat-
ment of a variety of diseases. Although the major effort in stem cell therapies in the past has been identifying
potentially therapeutic cells, it is now clear that developing systems to deliver these cells and promote their
efficient engraftment will provide an equally challenging task. More sophisticated pretransplantation manip-
ulations and material carriers may dramatically improve the survival, engraftment, and fate control of trans-
planted stem cells and their ultimate clinical utility.Introduction
Cell therapies promise to provide cures to a multitude of dis-
eases and disorders, frequently via tissue repair, which is the fo-
cus of this review. Stem cell populations, in particular, are ap-
pealing therapeutic agents due to their typically rapid and
extensive proliferation and their potential to customize the cells
to the patient. A stem cell has two characteristics in its basic
form: the ability to self-renew and the ability to maintain a differ-
entiated and functional cell type for the life of an organism. The
ability of a stem cell to form multiple functional cell types is an
additional, but not necessary, characteristic of many of the
currently studied embryonic and adult stem cells (Wagers and
Weissman, 2004). There has been tremendous progress over
the past decade in the identification of a variety of cell popula-
tions isolated from adult tissues that are capable of contributing
to the rebuilding of multiple tissues and organs (e.g., cardiac and
neural) (Filipczyk et al., 2007; Lee et al., 2007), the development
of techniques to direct the differentiation of embryonic stem cells
to desirable cell populations (e.g., pancreatic beta cells; Porat
andDor, 2007), and even recently the ability to reprogram human
adult cells into ES cell-like pluripotent cells (Takahashi et al.,
2007; Yu et al., 2007). The major challenge facing this field is to
transition rapidly from the identification of candidate cell popula-
tions to the development of effective delivery approaches.
Potential cell therapies are most typically introduced to the
body via an injection of cells, suspended in an appropriate
medium, either into the systemic circulation or directly into the
tissue of interest (Figure 1). A wide variety of cell populations
has been transplanted in thismanner, including variousmyoblast
populations, neural stem cells, hepatocytes, various bone mar-
row-derived cells, and ES cells differentiated down various path-
ways (Hofmann et al., 2005; Skuk et al., 2007; Evans et al., 2007;
Thuret et al., 2006; Porat and Dor, 2007). These studies have
confirmed the ability of transplanted cells to participate in the
repair of damaged or diseased tissue and demonstrated proof
of principle for this new therapeutic approach. The results of
many studies, however, are also making clear that at least
some of the transplanted cell populations regulate regeneration
via secretion of trophic factors, instead or in addition to directly
participating in building of the tissue (Mangi et al., 2003; Caponeet al., 2007). This latter mechanism suggests that appropriately
distributing transplanted cells in the host tissue may be critical
to their utility. In either case, however, studies have uniformly
demonstrated large-scale death of the transplanted cells, ex-
tremely poor engraftment (typically <3% cells engraft), and
loss of control over the fate of the transplanted cells after their
introduction into the body. The spread of the cells from the injec-
tion site is also typically quite restricted, seriously limiting the
scale of tissue repair in many situations. Together, these issues
are likely responsible for the limited clinical success of this ap-
proach to date and the repeated finding that success is greatest
in small tissue volumes (e.g., rodent models).
It may be possible to dramatically improve the impact of trans-
planted stem cell populations by borrowing concepts from the
tissue engineering field originally developed for the transplanta-
tion of differentiated cells (Langer and Vacanti, 1993; Griffith and
Naughton, 2002). In particular, the tissue engineering field
routinely makes use of material carriers, functioning as synthetic
analogs of the extracellular matrix, to provide a substrate for
transplanted cell adhesion, to control the localization of the cells
in vivo, and to serve as a template for the formation of new tissue
masses from the combination of transplanted cells and interfac-
ing host cells (Figure 1) (Lutolf and Hubbell, 2005; Sands and
Mooney, 2007). These functions may prevent anoikis in the
transplanted cells and also regulate their gene expression. Fur-
ther, the material’s ability to orchestrate the host response to
the transplanted cells (e.g., vascularization) may dramatically im-
prove their survival and function in the host environment. Clinical
success to date in tissue engineering approaches to cell trans-
plantation is mainly in the skin arena (Auger et al., 2004), but
proof of principle for the engineering of many tissue/organ types
has been demonstrated in both small and large animal models
(Nerem, 2007).
This reviewwill provide an overview of two complementary ap-
proaches, both the foci of active investigation, to enhance the
success of tissue repair strategies with cell transplantation: ma-
nipulation of the biology of cells in advance of their transplanta-
tion and the development of material carriers to manipulate
transplanted cells in vivo and orchestrate the host response. Se-
lect examples of these two approaches will be described toCell Stem Cell 2, March 2008 ª2008 Elsevier Inc. 205
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this field, and current challenges to progress, will also be exam-
ined. This reviewwill not specifically examine cell transplantation
approaches to treat blood disorders or cancer, as although these
share certain objectives and challenges with tissue repair, there
also exist considerable divergences between these areas of
application.
Manipulating Cells prior to Transplantation
Two general approaches have been taken for cell therapies. The
first has been rapid cell isolation and reapplication of the cells
with minimal manipulations, preferably without either the patient
or cells leaving the operating room (e.g., Moseley et al., 2006).
The second, more common approach has been cell isolation,
transport to the lab, and extensive in vitro manipulation before
reimplantation. Advantages of the former approach include min-
imal cost and minimal oversight by regulatory agencies such as
the FDA, whereas the latter approach is costly and requires ma-
nipulation of the cells under current Good Manufacturing Proto-
cols (cGMP) in clean rooms with extensive documentation and
close regulatory supervision (e.g., De Bie, 2007). The significant
Figure 1. Current Strategies for Cell Transplantation
Cells are multiplied in culture prior to transplantation or used with minimal ma-
nipulation after harvesting and then delivered by one of two strategies. Most
commonly (left branch), cells suspended in medium are directly injected into
the defective tissue or into the systemic circulation. The cells are expected
to home to the site of interest or stay at the site of injection, depending on
the particular application, but in either case, little guidance is provided to the
cells by the transplant system. Alternatively (right branch), cells may be
allowed to adhere to a material carrier, typically a biodegradable polymer,
in vitro, allowed to proliferate and differentiate within a bioreactor, and subse-
quently be implanted or injected on thematerial to localize the cells to a specific
anatomic site and signal to the adherent cells. The material serves as a tem-
plate to guide tissue formation and typically is designed to degrade in concert
with deposition of new extracellular matrix and cell proliferation (Taken from
Lee and Mooney, 2001; used with permission of the American Chemical Soci-
ety [ACS]).206 Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc.advantage of the latter is the ability to manipulate the potentially
therapeutic cells in vitro to ‘‘improve’’ their ability to treat the
targeted disease once reimplanted. The following is a brief sum-
mary of issues related to both the source of the therapeutic cells
and their in vitro manipulation prior to transplantation, using
examples primarily from the area of skeletal and cardiac muscle
repair.
Influence of Cell Source
Skeletal muscle has a well-defined muscle-specific progenitor
called the satellite cell, which is activated after muscle fiber dam-
age and which can rapidly repair the damage in situ in normal
healthy adults. These cells can be readily isolated from humans
by simple muscle needle biopsy protocols, can be expanded
in vitro to billions of cells, and can be reinjected in an attempt
to treat diseases, such as Duchennes muscular dystrophy, in
which the native cell population is depleted (Kapsa et al., 2003)
or heart ischemia inwhich endogenous progenitor cells aremiss-
ing (Menasche, 2007). In general, the results from these clinical
trials to date have been disappointing, primarily due to rapid
cell death after reimplantation. Recent in vitro studies have iden-
tified several other skeletalmuscle stem/progenitor cells thatmay
have a greater potential for skeletal or cardiac muscle repair than
the satellite cell (reviewed in Peault et al., 2007). Studies are un-
derway for their isolation, in vitro expansion, and reimplantation
to determine their repair potential (Sampaolesi et al., 2006; Zheng
et al., 2007). The in vivo repair capacity of these cells can be
enhanced by in vitro chemical manipulation, such as exposure
to nitric oxide before reimplantation (Sciorati et al., 2006). Incuba-
tion of human skeletal myoblasts in tissue culture with several
growth factors, including IGF1, also improved their survival
when implanted in vivo (Brimah et al., 2004). Sex-related differ-
ences in the stem cells used for skeletal muscle repair have
been observed (Deasy et al., 2007) andmay be an important con-
sideration for other tissue types. Further, the methods used to
isolate the stem cells can have a profound effect on their subse-
quent ability to regenerate into differentiated cells when trans-
planted in vivo. For example, adult mouse skeletal muscle satel-
lite cells isolated without the use of proteolytic enzymes were
several orders of magnitude more efficient in generating new
muscle tissue in vivo than satellite cells isolated by typical enzy-
matic digestion techniques (Collins et al., 2005). In some cases,
as few as seven satellite cells in their native extracellular matrix
and implanted in a muscle bed can form hundreds of new post-
mitotic muscle fibers in vivo. Enzymatic damage to cell surface li-
gands or receptors may be the cause of this reduced repair ca-
pacity. Hematopoietic stem cells (HSCs) are also routinely
isolated by nonenzymatic techniques.
Methods to differentiate human stem cells into cardiomyo-
cytes have been widely studied to date because damaged adult
heart tissue has an extremely poor regenerative capacity due to
few local cardiomyocyte precursor cells (Beltrami et al., 2003).
Functional cardiomyocytes arising from differentiating human
embryonic stem (hES) cells were initially isolated and expanded
in vitro, but at relatively low efficiency (Kehat et al., 2001). These
studies required the use of an irradiated mouse cell feeder layer,
which could prove problematic for clinical use because cultured
cells can incorporate foreign xenogeneic proteins and generate
a host immune response when implanted. Two other potential
drawbacks of early methods to yield human cardiomyocytes
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cells (up to 3 weeks) and the low percentage of embryoid bodies
containing contractile cells (10%). Recently, feeder layer-free
tissue culture conditions to generate contractile cardiomyocytes
have been described and used in subsequent in vivo transplant
studies (Laflamme et al., 2005). These studies used Matrigel as
a cell attachment substrate as well as tissue culture medium
conditioned by mouse embryonic fibroblasts, both of which
might also be problematic for clinical applications due to their
potential to induce an immune response. Attempts to use FDA-
approved matrix molecules, such as collagen (e.g., Zyderm),
as a cell carrier can also be problematic because they can be
highly antiangiogenic in vivo (Thorrez et al., 2006).
Chemical and Physical Manipulation
Many in vitro manipulations have been examined in an effort to
improve stem cell differentiation and engraftment. DMSO was
tested as a differentiation stimulant to enhance cardiomyocyte
yield but was found to be ineffective, whereas the addition of
retinoic acid to ES cell medium depleted undifferentiated cells
and improved cardiomyocyte yield (Zandstra et al., 2003). Serial
application in vitro of a mesendodermal inducing factor (activin
A) followed by a cardiac tissue differentiation factor (BMP4) to
hES cells led to a 50-fold increase in cardiomyocyte differentia-
tion, compared to serum, and enhanced engraftment in vivo.
Injection of these differentiated stem cells with Matrigel also
had beneficial effects on cell survival in vivo (Laflamme et al.,
2007), – possibly by preventing anoikis (Frisch and Screaton,
2001) (see next section). In vitro heat shock of the hES cardio-
myocytes (30 min at 43C 24 hr before implantation) was also
found to have a profound effect on survival and grafting of the
cells in vivo into undamaged hearts, with a 3-fold increase in
the graft size due to a continued high rate of proliferation of the
cells in vivo (Laflamme et al., 2005). Although the mechanism(s)
by which this simple protocol enhances transplant efficiency is
not fully understood, it is thought that these activated molecular
chaperones (Hsp60, Hsp70, and Hsp90) limited cell death. Of
course, continued proliferation of the transplanted cells in vivo
must be somehow controlled to prevent the formation of tera-
tomas.
Stem cells may require different manipulations ex vivo de-
pending on the site into which they are to be subsequently trans-
planted. For example, cardiomyocytes derived from hES cells
responded differently when implanted into an undamaged heart
compared to an area of infarction (Laflamme et al., 2007). Epithe-
lium-lined cysts occurred in the latter site, but not in the former.
The cause of this difference is unknown but may reflect level of
ischemia at the implant site, the state of the host repair process,
and/or the amount of scar tissue present. Mechanical strain on
the transplanted cells would also be different in the two sites
and could play a role in determining the fate of implanted stem
cells (Estes et al., 2004).
Stage of Cell Differentiation
The in vitro differentiation state of stem cells that leads to the
best survival in vivo is unknown in most instances. This issue is
also complicated by the possibility that differentiation of stem
cells in vitro may help reduce the formation of teratomas
in vivo (Laflamme et al., 2007) but limit cell survival. Transplanta-
tion of undifferentiated proliferating primary myoblasts led to
rapid cell death within several days (Skuk et al., 2003), whereasimplantation of differentiated postmitotic myofibers results in
a slower process of cell death over weeks rather than days (Thor-
rez et al., 2008). Cardiac ‘‘tissue-restricted’’ progenitor cells
(isl1+) have been isolated from the postnatal heart of rats,
mice, and humans, and the differentiation of these adult-derived
stem cells into the cardiomyocyte phenotype requires both
membrane-bound factors (coculturing with fixed rodent myo-
cytes) and soluble factors (conditioned medium from viable
rodent myocytes [Laugwitz et al., 2005]). These early-stage
progenitor cells may be more efficient than differentiated
cardiomyocytes for the growth of new heart tissue after trans-
plantation because they can give rise not only to cardiac cells
but also to other cell types (endothelial and smooth muscle cells)
required for cardiogenesis.
In Vitro Cell Growth in Three Dimensions
Bioreactors for stem cell growth in vitro may better reflect the
in vivo environment and be useful for the growth, differentiation,
and ‘‘conditioning’’ of stem cells for subsequent in vivo transplan-
tation. Nutrient and oxygen availability can be better regulated in
these systems than in monolayer cultures. Bioreactor spinner
flask perfusion conditions have been established to increase
the yield of cardiomyocytes per input ES cells (19.8-fold over
static conditions) by encapsulating the differentiating ES cells in
lowmelting temperature agarose tomaintain an efficient cell den-
sity for optimal cell growth; it was also shown that transient expo-
sure of the ES cells to hypoxic conditions improved cardiomyo-
cyte yield 1.47-fold (Bauwens et al., 2005). Hypoxia can also
augment the expansion of bone morrow-derived stem cells by
regulating telomerase activity in the cells (D’Ippolito et al.,
2004). Bioreactors have also been used to tissue engineer cardi-
omyocytes into contractile ‘‘tissues’’ (Radisic et al., 2004), and
engineered cardiac tissue from neonatal heart cells can be im-
planted successfully as a tissue patch to improve cardiac func-
tion in rodent hearts (Zimmermann et al., 2006). Recently, hES
cells were also engineered into contractile cardiac tissues (Rogge
et al., 2007) and thus might represent a vast, reliable cell source
for cardiac patch repair. Scaling up the engineered tissue ap-
proach for clinical applications will require significant improve-
ments in the capacity to generate large three-dimensional tissue
in vitro. Alternatively, it may be possible to promote the growth of
small engineered tissues subsequent to their introduction in vivo.
Bioreactor studies may prove vital for this approach.
Genetic Manipulation
Genetic manipulation in vitro to improve/enhance differentiation
function and transplantation efficiency of stem cells is another
active area of research. Transfection of ES cells with a neomy-
cin-resistant transgene linked to a myosin heavy chain promoter
was able to effectively enrich the ES cell population into cardio-
myocytes at greater than 70% efficiency (Zandstra et al., 2003).
Skeletal myoblasts, which have been transduced to express the
gap junction protein connexin 43, formed an enhanced network
of interconnected contractile cells in the heart (Roell et al., 2007),
potentially providing a good source of autologous adult stem
cells for heart repair. Genetically modifying stem cells to secrete
soluble factors may also enhance implantation efficiency. For
example, tissue engineering of human skeletal muscle with
myoblasts genetically engineered to secrete vascular endothelial
factor stimulated vascularization of the implant site (Thorrez
et al., 2006).Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc. 207
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Utilized as Cell Delivery Vehicles
Design criteria are often derived by combining the
known biology of the cell of interest (e.g., relevant
adhesion molecules and morphogens) with in vitro
studies using appropriate 3D models of tissue for-
mation to develop quantitative relations between
the cues and cell response. In this example, the
sprouting of endothelial cells into a surrounding
extracellular matrix-mimic (fibrin gel) from micro-
carrier beads (top image) may be used as a model
of sprouting angiogenesis, and the relation be-
tween the level and direction of sprouting and
morphogen concentration and spatial gradients
may be quantified. These designs are then trans-
lated to materials systems, using the tools of
chemistry and materials science and engineering.
These materials provide the desired cues with ap-
propriate spatiotemporal resolution to cells trans-
planted on the materials. Polymers, such as the
polysaccharide structure shown, are most often
used to create vehicles for cell transplantation.
The two general types of cues designed into the
material carriers include adhesive cues (e.g., spe-
cific adhesion ligands and number of bonds cells
formwith ligands) and control over time and space
of the availability of single or multiple morphogens
and cytokines to transplanted and host cells. The
image of the cell (green structure on bottom, left)
demonstrates FRET (red fluorescence) resulting
from a cell specifically adhering to adhesion
peptides coupled to the gel-forming polymer. The graphs (bottom, right) demonstrate waves of morphogen release over time from the polymers and resultant
spatial gradients (inset) in surrounding tissue (images taken from Huebsch and Mooney, 2007 and Chen et al., 2007b).Material Systems to Manipulate Transplanted
Cells and Host Response
Materials for cell transplantation have been traditionally de-
signed from a classic materials science perspective, in terms
of providing appropriate physical (e.g., strength) and chemical
(e.g., degradation rate) properties (Langer and Vacanti, 1993).
More recently, however, the design space for these materials
has expanded dramatically to include biological criteria that in-
clude a consideration of signals cells receive via adhesion to
the carrier and of soluble signals (e.g., morphogens) available
in the cellular microenvironment (Figure 2) (Lutolf and Hubbell,
2005; Kong andMooney, 2007). These various cues are intended
to orchestrate the host cell response, in addition to regulating the
transplanted cell population(s).
Quantitative biological design criteria will be critical for mate-
rials used for stem cell transplantation, as both the types and
quantities (e.g., concentrations, gradients in time and space) of
the cues provided by the material will likely play a crucial role
in signaling cell fate. An attractive approach to generating quan-
titative design criteria is to first develop a quantitative under-
standing of the relation between the cue and the target cell
population response. This information can often be obtained
by using three-dimensional (3D) cell culture models (Griffith
and Swartz, 2006) such as those described in the last section,
as they enable rapid screening of a typically large variable space.
The tools of materials science and engineering are then utilized
to design a material, most often a polymer, that provides this
cue to transplanted and host cells in the desired quantity over
time and space. For example, a 3D sprouting assay has been
used to delineate the role of concentrations and gradients of var-
ious morphogens on angiogenesis in vitro and design material
systems to promote angiogenesis in vivo (Chen et al., 2007a).208 Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc.Materials to Regulate Adhesion
Adhesion to a substrate is required to prevent anoikis and allow
transplanted cell survival over even short time frames, and ma-
nipulating the presentation of adhesive cues further allows one
to regulate major cellular processes (e.g., migration, prolifera-
tion, and differentiation) over longer time scales. A variety of nat-
urally derived ECMmolecules (e.g., type I collagen and fibrin) are
currently being used as cell vehicles due to their intrinsic cell
binding capabilities, as are synthetic polymers to which adhe-
sion is regulated by adsorbed proteins (Silva and Mooney,
2004). Synthetic peptides mediating adhesion can also be pre-
sented to cells as self-assembling hydrogels, coupled as side
chains to polymer backbones, or as components of synthetic
proteins that provide desirable combinations of cell interactive
domains and overall physical/chemical properties (Gelain et al.,
2006; Lutolf and Hubbell, 2005; Silva et al., 2004). The utility of
approaches presenting specific adhesion peptides depends on
the absence of nonspecific adhesion to enable a high ‘‘signal’’
to ‘‘noise’’ ratio in the system. Strikingly, even when an identical
adhesive peptide is utilized at a constant overall density, its clus-
tering and spacing on a nanometer scale can dramatically alter
the cell response and enhance or diminish processes such as
proliferation or differentiation (Maheshwari et al., 2000; Comisar
et al., 2007). In addition to the chemistry of the cell-material inter-
face, themechanics of this interface are being recognized to play
a key role in the cell response (Discher et al., 2005). In particular,
the differentiation of adult tissue-derived progenitor populations
in vitro is controlled in part by the stiffness of the adhesion sub-
strate (Chen, 2004; Engler et al., 2006; Gwak et al., 2007). How-
ever, it is not clear if these findings result from an inductive or
permissive effect (e.g., selection of a subset of the population);
in addition, distinct roles may be played by adhesive cues in
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A variety of materials for cell delivery are under
development, and these materials must typically
function to deliver the cells in a minimally invasive
manner, allow for delivery of single or mixed cell
populations, and cue transplanted cells to orga-
nize into a new tissue capable of responding to
host signals.
(A) Injectable hydrogels are often used to trans-
plant cells with minimally invasive techniques
and can localize the cells to a desired anatomic
site and provide instruction to the cells.
(B) The challenges of engineering growth plate-like
structures are representative of the complex func-
tion required of these materials. In this example,
injectable gels presenting appropriate cell adhe-
sion peptides were used to cotransplant mixed
cell populations and cue the cells to reorganize into structures that both histologically resembled growth plates and were also functionally similar to growth plates
in their ability to increase in size over time (Alsberg et al., 2002). Cartilage, mineralized tissue, and bone marrow were formed 26 weeks after transplantation into
rodents in this study, and the organization and morphology of the cells were virtually identical to those found in normal growth plates (image taken from Alsberg
et al., 2002).more primitive versus more committed cell populations (Hsiong
et al., 2007). The development of more sophisticated tools to
probe and quantify molecular level events at the cell-material in-
terface (Kong et al., 2006; Sniadecki et al., 2007) will significantly
improve our ability to understand and ultimately regulate these
events via materials designed to trigger predefined signal trans-
duction pathways.
Controlling Regeneration with Adhesive Cues
Controlling the adhesive cues presented to transplanted cells
has dramatically impacted their survival and their ability to both
form new tissue structures and participate in regeneration of
damaged tissues (Alsberg et al., 2002; Davis et al., 2005; Hill
et al., 2006). The density of Notch ligand binding sites, for exam-
ple, can impact the engraftment of human cord blood progenitor
cells (Delaney et al., 2005). Hydrogels can be introduced into the
body byminimally invasive techniques (Figure 3A) and have been
used to present specific adhesive peptides in desirable patterns
to transplanted cells, promoting the formation of complex, tis-
sue-specific structures (Figure 3B) (Alsberg et al., 2002).
However, the ability of progenitor populations, as contrasted to
committed cell populations, to participate in regeneration has
been found to be dependent in some studies on the provision
of a more complex microenvironment (e.g., adhesive ligands in
concert with appropriate growth factors; see next section) (Sim-
mons et al., 2004; Huang et al., 2005a). There has not yet been
a definitive demonstration that the mechanical properties of
the adhesion substrate regulate tissue formation by transplanted
cells in vivo. This likely relates to the difficulty in separating me-
chanical and degradative properties of materials, and the mate-
rial degradation rate clearly plays an important role in the ability
of transplanted cells to deposit new matrix and remodel the tis-
sue (Alsberg et al., 2003; Benoit et al., 2006). The development
and application of new materials in which the degradative and
mechanical properties can be decoupled will undoubtedly aid
these studies and potentially provide another control point for
cell fate following transplantation.
Regulating Presentation of Soluble Cues
The local presentation of soluble cues (e.g., morphogens) from
material carriers may be utilized to regulate the fate of trans-
planted and host cell populations as they together repair tissues.Extensive research has been performed over the last 30 years to
develop suitable microenvironments for HSC expansion and di-
rected differentiation (reviewed in Panoskaltsis et al., 2005). At-
tempts to mimic the HSC niche in vitro have utilized exogenous
growth factors in combination with 2D and 3D scaffolds and bio-
reactor perfusion systems. Other stem cell repair systems may
also need to simulate growth-differentiating factors in a pharmo-
kinetic manner that mimics the natural stem cell niche by provid-
ing exogenous growth factors to the cells on 2D and 3D scaf-
folds. In the simplest approach, cytokines, morphogens, and
growth factors that regulate survival, proliferation, and/or differ-
entiation may be physically encapsulated, covalently coupled, or
associated via secondary bonding with the cell transplantation
vehicle. The factors may be subsequently presented in vivo
with high local concentrations, defined gradients, and low
systemic exposure, via release controlled by either material
degradation or factor diffusion from the material (Tessmar and
Go¨pferich, 2007). Specific examples of this approach include
improvements in the efficacy of transplanted cardiomyoctes in
mediating myocardial infarction via presentation of IGF from
the carrier (Davis et al., 2005), presenting TGF-b and BMP-4 to
enhance the ability of transplanted mesenchymal stem cells to
form bone (Simmons et al., 2004; Park et al., 2007), and EGF de-
livery to increase keratinocyte-driven epidermis regeneration
(Gwak et al., 2007). Release of antiapoptotic cytokines could po-
tentially also be used to enhance the short-term survival of trans-
planted cells, as demonstrated for resident host cells (He´rodin
et al., 2003). Appropriate compartmentalization of multiple
agents can provide their simultaneous or sequential delivery
(Chen et al., 2007b), which may allow multiple distinct stages
of cell differentiation and tissue formation to be orchestrated
by the material.
Local Gene Therapy for Regeneration
In place of direct protein delivery, the cell delivery vehicle may be
designed to provide oligonucleotides (e.g., plasmid DNA [pDNA]
and siRNA) to mediate local morphogen production. Sustained
release of pDNA from material carriers and surface presentation
of pDNA can dramatically increase transfection levels in vivo
(Bonadio et al., 1999; Shea et al., 1999; Houchin-Ray et al.,
2007). More recently, the condensation of pDNA into small par-
ticles, using polycations, prior to encapsulation into polymersCell Stem Cell 2, March 2008 ª2008 Elsevier Inc. 209
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Resident Cells
Appropriately designed material systems may be
used to either transplant cells or recruit resident
cell populations, using appropriate signaling (1).
In either case, once cells are in contact with the
material system, it may be designed to program
the cells in situ by the presentation of appropriate
adhesive cues, morphogens, and/or genetically
modifying the cells (2). Programming would often
include activating the cells to a highly proliferative
state in order to generate large numbers of daugh-
ter cells, controlling the state of differentiation, and
ultimately promoting a continuous dispersion of
appropriately differentiated daughter cells to the
tissue immediately adjacent or at a distance to
the material. This concept was recently demon-
strated with muscle-derived satellite cell popula-
tions, as a material carrier providing appropriate
adhesion ligands and growth factors was demonstrated to activate the cells into a proliferative state, prevent their terminal differentiationwhile within thematerial,
and provide an efficient repopulation of damagedmuscle tissue by the transplanted cells, with a significant increase in muscle regeneration (3) (image taken from
Hill et al., 2006).has been demonstrated to significantly increase tranfection
levels, via increased uptake efficiency and sustained presenta-
tion to cells (Huang et al., 2005b). Importantly, microenvironmen-
tal cues, including the density and organization of adhesion li-
gands and matrix mechanical properties, strongly regulate the
ability of cells to uptake and express pDNA (Kong et al., 2005,
2007), again emphasizing the importance of designing the over-
all microenvironment of transplanted cells, and not simply one
element in isolation of the other variables. Although not ad-
dressed to date, the controlled delivery of siRNA to transplanted
cells holds significant promise to regulate tissue repair.
Host Integration
A significant challenge to the successful implementation of cell
therapies is the integration of the new cells with the vascular,
lymphatic, and nervous systems of the host. Toward this end,
factors released from delivery vehicles may diffuse into the sur-
rounding tissue to create gradients (Silva and Mooney, 2007) in
order to activate host cells and guide their ingrowth into the cell
transplantation site. The need for vascularization is motivated by
the observation that transplanted cells will rapidly die if they are
placed a significant distance from the host vasculature (Skuk
et al., 2007), and one approach to address this issue is to drive
angiogenesis at the site of cell transplantation. Material systems
that provide local and sustained presentation of angiogenic mol-
ecules have been demonstrated to enhance vascularization and
perfusion of the implant site (Sun et al., 2005; Trentin et al., 2006;
Rajangam et al., 2006) and increase the survival of transplanted
cells and tissue formation (Huang et al., 2005a). This process
may be further manipulated by sequential delivery of factors
involved in the initiation (e.g., VEGF) versus maturation (e.g.,
PDGF) of vessels, allowing temporal and spatial control over
vascular bed formation (Richardson et al., 2001). Alternatively,
transplantation of endothelial cells or progenitors in concert
with the cell type of interest may also contribute to the formation
of a new vascular network that enhances cell survival and tissue
formation (Nor et al., 1999; Levenberg et al., 2005). Homing of
circulating endothelial progenitor cells may also be promoted
by providing appropriate cues (Hristov et al., 2007) from the
cell delivery vehicle. Although there has been little effort to ac-
tively drive formation of a new lymphatic system (Niklason
et al., 2002), the systems and approaches developed to drive210 Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc.angiogenesis may prove useful for this application. In contrast
to the intensive efforts to drive vascularization at the sites of
cell transplantation, there has been relatively little progress to-
ward understanding and regulating innervation in engineered tis-
sues. A number of approaches to nerve regeneration, often in-
volving electrical, chemical, or topographic stimulation (Gomez
and Schmidt, 2007; Kapur and Shoichet, 2004), are being ac-
tively pursued, but only a few studies have noted structures sug-
gestive of nerves in tissues forming from transplanted cells
(Oberpenning et al., 1999; Grikscheit et al., 2004). Recently, re-
innervation of engineered muscle tissue was noted when cells
were implanted adjacent to transected nerve (Dwahan et al.,
2007). A lack of innervation will likely prevent full function and
lead to atrophy in many situations, even if phenotypically normal
tissue structures are formed initially by transplanted cells. The
recent recognition of significant molecular crosstalk between
the nervous and vascular systems (Zacchigna et al., 2008) dur-
ing development and regenerative processes may provide mul-
tiple targets to simultaneously enhance innervation and vascu-
larization.
Summary and Future Directions
Historically, most cell transplantation studies have utilized sim-
ple cell injections or infusions, but there has been considerable
progress recently in the development of more sophisticated
strategies that utilize pretransplant cell manipulations and mate-
rial carriers to alter cell fate in vivo. Identification of the appropri-
ate cell type(s), soluble and insoluble cues needed to direct the
fate of embryonic and adult stem cells, as well as genetic and
tissue engineering of the cells will likely be important steps in
the future manufacturing of successful clinical products. The
fundamental questions of which approach or combination of ap-
proaches will lead to the most successful cell engraftment, sur-
vival, and physiological functioning will ultimately depend on the
disease to be treated, the method/site of implantation, as well as
the health status of the individual patient to be treated andwill re-
quire extensive additional basic research. Material carriers may
be particularly useful to quantitatively control and manipulate
not only the fate of the transplanted cells but also host cell pop-
ulations (e.g., vascular progenitors) that may contribute to tissue
repair. Although current systems demonstrate incremental
Cell Stem Cell
Reviewadvances in transplanted cell utility, strategies that integrate
multiple cues into one system may provide dramatic improve-
ments in the future.
A number of significant challenges remain formaterial systems
used as carriers for transplanted cells. There exists a substantial
variable space inherent to these systems as they combine vari-
ous cues (e.g., types, densities, organization of adhesion li-
gands, presentation of various cytokines, and growth factors),
and the development of large-scale screening approaches (An-
derson et al., 2004; Fok and Zandstra, 2005) will be required to
thoroughly and systematically examine this space in order to de-
sign optimal material systems. This will likely require better 3D
in vitro model systems, and a combined experimental and in
silico approach (Vaziri and Gopinath, 2008). The successful vas-
cularization of tissue repair sites using delivery of angiogenic
molecules or cells is rapidly increasing the size scale of tissue re-
pair (e.g,. from hundreds of microns to millimeter scale in thick-
ness). However, it will likely be necessary to engineer complete
vascular networks, containing both conducting and distributing
vessels, if one is to repair centimeter-thick tissues, and micro-
fabrication techniques that predefine vascular trees over this
size scale may provide a path toward this goal (Borenstein
et al., 2007). The identification of specific pathways that actively
resolve inflammation (Serhan et al., 2007) may also provide new
targets for material-regulated vascularization and, more broadly,
microenvironmental control over transplanted cell fate. Clearly,
the use of allogeneic cells may dramatically increase the utility
of stem cell therapies, and it may be possible to design the ma-
terial delivery systems to also manipulate the host immune sys-
tem to induce tolerance (Reddy et al., 2006).
Cell delivery systems in the future will likely continue to take in-
spiration from the specialized microenvironments or niches,
which contain and controllably activate stem cell populations
within tissues (Mitsiadis et al., 2007). It may even be possible
to design cell transplantation vehicles that serve to localize and
maintain the viability of the transplanted cells, activate the cells
to a proliferative state, and induce daughter cells to migrate out-
ward over time to provide a continuous flow of cells at the opti-
mal differentiation state for their participation in regeneration
(Figure 4). These types of systems may also be designed in the
future to enhance the homing of exogenous (Min et al., 2006)
or endogenous progenitor cells (Hristov et al., 2007; Goldman,
2007) prior to local, material-controlled programming and redis-
persion to sites of tissue repair. These two conceptsmay be use-
ful for a wide array of stem cell populations.
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